Dermatology

Experts discuss bimekizumab for the treatment of psoriasis highlighting is efficacy over other treatments.

This analysis highlighted several trends in search volume regarding eczema, including correlations with weather and climate.

The extent of stigma significantly differs based on disease visibility and severity among children with chronic skin disorders.

New phase 3b/4 trial data compared both drugs efficacy and safety profiles for eczema patients, looking at adults and adolescents.

A new study found intensive topical therapy improves deep sleep and REM sleep for patients with psoriasis and atopic dermatitis after 2 weeks.

Abeona's pz-cel is up for indicated use to treat patients with recessive dystrophic epidermolysis bullosa.

Eblasakimab shows promising itch relief in dupilumab-experienced atopic dermatitis patients, with significant reductions in symptoms observed.

This presentation at ACP Internal Medicine 2024 covered key skills Colven believes internists should know for identification of dermatologic conditions.

Experts emphasize the importance of collaboration with infectious disease specialists for patients with tuberculosis, while highlighting the low reactivation rates in newer agents.

These data represent the largest single-center, long-term study on booster vaccines at a public hospital’s dermatology department in Japan.

This analysis compared the efficacy of a 5 mg daily dose of oral minoxidil to topical minoxidil, 5%, among male alopecia patients.

Experts highlight how a history of cancer may impact psoriasis treatment decisions while touching on the safety profiles of newer IL agents.

Experts discuss common comorbidities for patients with plaque psoriasis and how they can impact treatment decisions.

Dermatology physician assistants review the short- and long-term clinical trial data on deucravacitinib.

Dermatology physician assistants review the laboratory and monitoring requirements for TYK2 inhibitors deucravacitinib.

These data highlight the frequency of adverse events with narrow-band UVB phototherapy and concomitant therapy.

This analysis was conducted to address the fact that, while there are various acne specific instruments to assess quality of life domains, none exist to focus on all of the domains.

This study’s investigators point to the necessity of adapting an antibiotic stewardship program for acne treatment, with evaluation being done in dermatology practices to assess performance.

In these data, investigators had investigated the international differences in topical AK medication implementation, including links to countries’ different economic statuses.

Experts discuss the landscape of IL therapies for the treatment of psoriasis, highlighting their improved safety and efficacy over prior agents.

Experts discuss the use of TNF blockers in treating plaque psoriasis and their limited but important uses today.

TJ Chao and Kristine Kucera, PA’s go into dept of the recent developments in the systemic oral space of plaque psoriasis.

Physician assistants TJ Chao and Kristine Kucera discuss how the understanding of plaque psoriasis has changed over time and is now considered a systemic disease.

The FDA announcement on bimekizumab’s supplemental Biologics License Application followed the phase 3 BE HEARD I and II studies’ conclusion.

This analysis was conducted to evaluate the burden and disease characteristics of all 3 types of HAE among a set of Canadian patients.